KalVista Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 150
- Market Cap
- $546.2M
- Website
- http://www.kalvista.com
- Introduction
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.
Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)
- Conditions
- Diabetic Macular Edema
- Interventions
- Other: Sham ProcedureDrug: KVD001 Injection
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- KalVista Pharmaceuticals, Ltd.
- Target Recruit Count
- 129
- Registration Number
- NCT03466099
- Locations
- 🇺🇸
KalVista Investigative Site, Silverdale, Washington, United States
🇺🇸KalVIsta Investigative Site, Austin, Texas, United States
A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME
- Conditions
- Diabetic Macular Edema
- Interventions
- Drug: KVD001 Injection
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- KalVista Pharmaceuticals, Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT02193113
- Locations
- 🇺🇸
Raj K. Maturi, MD PC, Indianapolis, Indiana, United States
🇺🇸Beetham Eye Institute, Boston, Massachusetts, United States
🇺🇸Palmetto Retina Center, West Columbia, South Carolina, United States